Released Aug 8, 2022, after the close
10-Q filed Aug 9, 2022, 40 days after period end · 0001162194-22-000091
Q2 2022 · 10-Q
Revenue$18.78M$18.78M −39.5% vs Q2 2021−29.2% vs Q1 2022
Net Income-$63.54M-$63.54M N/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.82-$0.82 N/M vs Q2 2021N/M vs Q1 2022
Gross Profit$4,427,000—
Operating Income-$38,563,000N/M
Operating Cash Flowderived-$29,988,000N/M
Free Cash Flowderived-$30,926,000N/M
Margins · derived
Gross margin23.6%
Operating margin-205.4%−149.7 pt vs Q2 2021
Net margin-338.4%−283.1 pt vs Q2 2021
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $18.78M | $31.02M | $26.06M | $28.20M |
| Net Income | -$63.54M | -$17.14M | -$13.02M | -$13.75M |
| EPS Diluted | -$0.82 | -$0.23 | -$0.18 | -$0.20 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR